Log In
Wednesday 20th June 2018

Flu vaccine development

4th May 2006

The U.S. Health and Human Services Department have awarded five companies, including GlaxoSmithKline, more than $1 billion (540 million pounds) in contracts to develop new and better influenza vaccines.

The companies will all work to develop cell based-vaccines to fight influenza; GlaxoSmithKline was awarded $274.75 million (148.60 million pounds), MedImmune was awarded $169.46 million, Novartis AG won $220.51 million, DynPort vaccine, working with Baxter International Inc. , won $40.97 million and Solvay won $298.59 million.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2018